Biodegradable and amphiphilic block copolymer-doxorubicin conjugate as polymeric nanoscale drug delivery vehicle for breast cancer therapy

Biomaterials

Volumn 34, Issue 33, 2013, Pages 8430-8443

  Yang, Yang ^a   Pan, Dayi ^a   Luo, Kui ^a   Li, Li ^a   Gu, Zhongwei ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Biodegradation; Biosafety; Block polymer; Breast cancer; HPMA copolymer; Polymeric nanoparticle

Indexed keywords

ATOMIC FORCE MICROSCOPE (AFM); BIOSAFETY; BREAST CANCER; HPMA COPOLYMERS; HYDROPHILIC AND HYDROPHOBIC; IMMUNOHISTOCHEMICAL ANALYSIS; POLYMERIC NANOPARTICLES; THE SCANNING ELECTRON MICROSCOPES (SEM);

ATOMIC FORCE MICROSCOPY; BIODEGRADATION; BLOCK COPOLYMERS; CELL DEATH; DISEASES; DRUG DELIVERY; ENZYMES; MAMMALS; MOLECULES; NANOPARTICLES; ONCOLOGY; SCANNING ELECTRON MICROSCOPY; TOXICITY; TUMORS; VEHICLES;

BIODEGRADABLE POLYMERS;

AMPHOPHILE; COPOLYMER; DOXORUBICIN; DRUG VEHICLE; NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATOMIC FORCE MICROSCOPY; BIODEGRADABILITY; BREAST CANCER; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG CONJUGATION; DRUG CYTOTOXICITY; FEMALE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPE;

MURINAE; MUS;

BIODEGRADATION; BIOSAFETY; BLOCK POLYMER; BREAST CANCER; HPMA COPOLYMER; POLYMERIC NANOPARTICLE;

ANIMALS; BREAST NEOPLASMS; DOXORUBICIN; DRUG DELIVERY SYSTEMS; FEMALE; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MICE, INBRED BALB C; POLYMETHACRYLIC ACIDS;

EID: 84881669612     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.07.037     Document Type: Article

References (50)

1. Davis M.E. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008, 7:771-782.
2. Farokhzad O.C., Langer R. Impact of nanotechnology on drug delivery. ACS Nano 2009, 3:16-20.
3. Liu Y., Li K., Liu B., Feng S.-S. Astrategy for precision engineering of nanoparticles of biodegradable copolymers for quantitative control of targeted drug delivery. Biomaterials 2010, 31:9145-9155.
4. Cheng R., Meng F., Deng C., Klok H.-A., Zhong Z. Dual and multi-stimuli responsive polymeric nanoparticles for programmed site-specific drug delivery. Biomaterials 2013, 34:3647-3657.
5. Chen C.-Y., Kim T.H., Wu W.-C., Huang C.-M., Wei H., Mount C.W., et al. pH-dependent, thermosensitive polymeric nanocarriers for drug delivery to solid tumors. Biomaterials 2013, 34:4501-4509.
6. Kusi-Appiah A.E., Vafai N., Cranfill P.J., Davidson M.W., Lenhert S. Lipid multilayer microarrays for invitro liposomal drug delivery and screening. Biomaterials 2012, 33:4187-4194.
7. Chen M.-C., Sonaje K., Chen K.-J., Sung H.-W. Areview of the prospects for polymeric nanoparticle platforms in oral insulin delivery. Biomaterials 2011, 32:9826-9838.
8. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 2006, 6:688-701.
9. Kopeček J., Kopečková P. HPMA copolymers: origins, early developments, present, and future. Adv Drug Deliv Rev 2010, 62:122-149.
10. Alexis F., Pridgen E., Molnar L.K., Farokhzad O.C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharmacol 2008, 5:505-515.
11. Campone M., Rademaker-Lakhai J.M., Bennouna J., Howell S.B., Nowotnik D.P., Beijnen J.H., et al. Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients. Cancer Chemother Pharmacol 2007, 60:523-533.
12. Vasey P.A., Kaye S.B., Morrison R., Twelves C., Wilson P., Duncan R., et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl) methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Clin Cancer Res 1999, 5:83-94.
13. Matsumura Y., Hamaguchi T., Ura T., Muro K., Yamada Y., Shimada Y., et al. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br J Cancer 2004, 91:1775-1781.
14. Hopewell J., Duncan R., Wilding D., Chakrabarti K. Preclinical evaluation of the cardiotoxicity of PK2: a novel HPMA copolymer-doxorubicin-galactosamine conjugate antitumour agent. Hum Exp Toxicol 2001, 20:461-470.
15. Maeda H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug Chem 2010, 21:797-802.
16. Kopeček J. Polymer-drug conjugates: origins, progress to date and future directions. Adv Drug Deliv Rev 2012, 65:49-59.
17. Lammers T., Kühnlein R., Kissel M., Subr V., Etrych T., Pola R., et al. Effect of physicochemical modification on the biodistribution and tumor accumulation of HPMA copolymers. JControl Release 2005, 110:103-118.
18. Allmeroth M., Moderegger D., Biesalski B., Koynov K., Rösch F., Thews O., et al. Modifying the body distribution of HPMA-based copolymers by molecular weight and aggregate formation. Biomacromolecules 2011, 12:2841-2849.
19. Seymour L., Duncan R., Strohalm J., Kopeček J. Effect of molecular weight (Mw) of N-(2-hydroxypropyl) methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal, and intravenous administration to rats. JBiomed Mater Res 1987, 21:1341-1358.
20. Pan H., Yang J., Kopečková P., Kopeček J. Backbone degradable multiblock N-(2-hydroxypropyl) methacrylamide copolymer conjugates via reversible addition-fragmentation chain transfer polymerization and thiol-ene coupling reaction. Biomacromolecules 2010, 12:247-252.
21. Luo K., Yang J., Kopečková P., Kopeček J. Biodegradable multiblock poly[N-(2-hydroxypropyl) methacrylamide] via reversible addition-fragmentation chain transfer polymerization and click chemistry. Macromolecules 2011, 44:2481-2488.
22. 1 conjugate in promotion of bone formation in ovariectomized rats. Biomaterials 2013, 34:6528-6538.
23. Zhang R., Luo K., Yang J., Sima M., Sun Y., Janát-Amsbury M.M., et al. Synthesis and evaluation of a backbone biodegradable multiblock HPMA copolymer nanocarrier for the systemic delivery of paclitaxel. JControl Release 2012, 166:66-74.
24. Pan H., Sima M., Yang J., Kopeček J. Synthesis of long-circulating, backbone degradable HPMA copolymer-doxorubicin conjugates and evaluation of molecular-weight-dependent antitumor efficacy. Macromol Biosci 2013, 13:155-160.
25. Lalatsa A., Schätzlein A.G., Mazza M., Le T.B.H., Uchegbu I.F. Amphiphilic poly(L-amino acids)-new materials for drug delivery. JControl Release 2012, 161:523-536.
26. Zhang C.Y., Yang Y.Q., Huang T.X., Zhao B., Guo X.D., Wang J.F., et al. Self-assembled pH-responsive MPEG-b-(PLA-co-PAE) block copolymer micelles for anticancer drug delivery. Biomaterials 2012, 33:6273-6283.
27. Wang Y., Grayson S.M. Approaches for the preparation of non-linear amphiphilic polymers and their applications to drug delivery. Adv Drug Deliv Rev 2012, 64:852-865.
28. Prabaharan M., Grailer J.J., Pilla S., Steeber D.A., Gong S. Amphiphilic multi-arm-block copolymer conjugated with doxorubicin via pH-sensitive hydrazone bond for tumor-targeted drug delivery. Biomaterials 2009, 30:5757-5766.
29. Yang Y., Cai J., Zhuang X., Guo Z., Jing X., Chen X. pH-dependent self-assembly of amphiphilic poly(L-glutamic acid)-block-poly(lactic-co-glycolic acid) copolymers. Polymer 2010, 51:2676-2682.
30. Li J., Ren J., Cao Y., Yuan W. Synthesis of biodegradable pentaarmed star-block copolymers via an asymmetric BIS-TRIS core by combination of ROP and RAFT: from star architectures to double responsive micelles. Polymer 2010, 51:1301-1310.
31. Hinton T.M., Guerrero-Sanchez C., Graham J.E., Le T., Muir B.W., Shi S., et al. The effect of RAFT-derived cationic block copolymer structure on gene silencing efficiency. Biomaterials 2012, 33:7631-7642.
32. Li W., Li J., Gao J., Li B., Xia Y., Meng Y., et al. The fine-tuning of thermosensitive and degradable polymer micelles for enhancing intracellular uptake and drug release in tumors. Biomaterials 2011, 32:3832-3844.
33. She W., Luo K., Zhang C., Wang G., Geng Y., Li L., et al. The potential of self-assembled, pH-responsive nanoparticles of mPEGylated peptide dendron-doxorubicin conjugates for cancer therapy. Biomaterials 2012, 34:1613-1623.
34. She W., Li N., Luo K., Guo C., Wang G., Geng Y., et al. Dendronized heparin-doxorubicin conjugate based nanoparticle as pH-responsive drug delivery system for cancer therapy. Biomaterials 2013, 34:2252-2264.
35. Ulbrich K., Šubr V., Strohalm J., Plocova D., Jelínková M., Říhová B. Polymeric drugs based on conjugates of synthetic and natural macromolecules: I. synthesis and physico-chemical characterisation. JControl Release 2000, 64:63-79.
36. Yang J., Luo K., Pan H., Kopečková P., Kopeček J. Synthesis of biodegradable multiblock copolymers by click coupling of RAFT-generated heterotelechelic polyHPMA conjugates. React Funct Polym 2011, 71:294-302.
37. Kopeček J., Baẑilová H. Poly[N-(2-hydroxypropyl) methacrylamide]-I. radical polymerization and copolymerization. Eur Polym J 1973, 9:7-14.
38. Mitsukami Y., Donovan M.S., Lowe A.B., McCormick C.L. Water-soluble polymers. 81. direct synthesis of hydrophilic styrenic-based homopolymers and block copolymers in aqueous solution via RAFT. Macromolecules 2001, 34:2248-2256.
39. Rejmanová P., Kopeček J., Duncan R., Lloyd J.B. Stability in rat plasma and serum of lysosomally degradable oligopeptide sequences in N-(2-hydroxypropyl) methacrylamide copolymers. Biomaterials 1985, 6:45-48.
40. Tang R., Ji W., Panus D., Palumbo R.N., Wang C. Block copolymer micelles with acid-labile ortho ester side-chains: synthesis, characterization, and enhanced drug delivery to human glioma cells. JControl Release 2011, 151:18-27.
41. MacKay J.A., Chen M., McDaniel J.R., Liu W., Simnick A.J., Chilkoti A. Self-assembling chimeric polypeptide-doxorubicin conjugate nanoparticles that abolish tumours after a single injection. Nat Mater 2009, 8:993-999.
42. Cho K., Wang X., Nie S., Shin D.M. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008, 14:1310-1316.
43. Aggarwal P., Hall J.B., McLeland C.B., Dobrovolskaia M.A., McNeil S.E. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev 2009, 61:428-437.
44. Yilmaz M., Christofori G., Lehembre F. Distinct mechanisms of tumor invasion and metastasis. Trends Mol Med 2007, 13:535-541.
45. Blagosklonny M.V. Antiangiogenic therapy and tumor progression. Cancer Cell 2004, 5:13-17.
46. Urruticoechea A., Smith I.E., Dowsett M. Proliferation marker Ki-67 in early breast cancer. JClin Oncol 2005, 23:7212-7220.
47. Tinnikov A.A., Yeung K.T., Das S., Samuels H.H. Identification of a novel pathway that selectively modulates apoptosis of breast cancer cells. Cancer Res 2009, 69:1375-1382.
48. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
49. Nori A., Kopeček J. Intracellular targeting of polymer-bound drugs for cancer chemotherapy. Adv Drug Deliv Rev 2005, 57:609-636.
50. Evan G.I., Vousden K.H. Proliferation, cell cycle and apoptosis in cancer. Nature 2001, 411:342-348.